13F filerCIK 1061768 ↗
Baupost Group
You are looking at Q1 2018. See the latest, Q3 2026 →
Reported value
$10.37B
+2.5% on the quarter before
Positions
33
2 new, 3 sold out
Top 10
76.5%
of the value
Est. gain
−$325.7M
on stocks held all quarter
Est. return
−3.3%
on those stocks since Q4 2017
Positions as of Mar 31, 2018, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2017. Striped tiles are options.
Largest buys
Since Q4 2017, sized at quarter-end prices.
- Pioneer Nat Res Co~$343.6MAdded, 3.4% → 6.6% of the portfolio+2,000,000 shares
- Twenty First Centy Fox Inc~$157.8MAdded, 7.6% → 9.4% of the portfolio+4,300,000 shares
- Pg&E Corp~$138.4MNew, 0.0% → 1.3% of the portfolio+3,149,972 shares
- Tesla~$52.2MNew, 0.0% → 0.5% of the portfolio+50,000,000 shares
- Allergan Plc~$42.1MAdded, 7.3% → 7.7% of the portfolio+250,000 shares
- Antero Res Corp~$37.0MAdded, 4.6% → 5.1% of the portfolio+1,865,604 shares
- Mckesson Corp~$36.0MAdded, 2.1% → 2.2% of the portfolio+255,700 shares
- Atara Biotherapeutics Inc~$34.9MAdded, 1.0% → 2.4% of the portfolio+895,000 shares
- Viasat Inc~$32.9MAdded, 9.7% → 8.7% of the portfolio+500,000 shares
- Twenty First Centy Fox Inc~$32.8MAdded, 3.6% → 4.0% of the portfolio+902,100 shares
Largest sells
Since Q4 2017, sized at quarter-end prices.
- Express Scripts Hldg Co~$172.2MSold out, 1.7% → 0.0% of the portfolio−2,306,456 shares
- Pbf Energy Inc~$101.7MCut, 3.8% → 2.6% of the portfolio−3,000,000 shares
- Cascadian Therapeutics Inc~$32.3MSold out, 0.3% → 0.0% of the portfolio−8,721,079 shares
- Sunrun Inc~$16.8MSold out, 0.2% → 0.0% of the portfolio−2,848,082 shares
- Amerisourcebergen Corp~$10.1MCut, 1.3% → 1.1% of the portfolio−117,349 shares
- ChipMOS Technologies~$8.5MCut, 0.3% → 0.1% of the portfolio−536,750 shares
- Forward Pharma A/S~$2.9MCut, 0.2% → 0.1% of the portfolio−1,331,937 shares
Holdings
As of Mar 31, 2018; changes in shares since Dec 31, 2017.
| Holding | Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cheniere Energy IncCOM NEW · shares 0% · price −0.7% | 10.7% | $1.11B | −$8.1M | ||||||
| Synchrony FinlCOM · shares 0% · price −13.2% | 9.5% | $982.3M | −$148.8M | ||||||
| Twenty First Centy Fox IncCL A · shares +19% · price +6.3% | 9.4% | $975.5M | +$48.1M | ||||||
| Viasat IncCOM · shares +3.8% · price −12.2% | 8.7% | $897.6M | −$120.1M | ||||||
| Allergan PlcSHS · shares +5.6% · price +2.9% | 7.7% | $799.4M | +$21.2M | ||||||
| QorvoCOM · shares 0% · price +5.8% | 7.5% | $775.0M | +$42.4M | ||||||
| Time Warner IncCOM NEW · shares 0% · price +3.4% | 7.4% | $766.1M | +$25.2M | ||||||
| Pioneer Nat Res CoCOM · shares +100% · price −0.6% | 6.6% | $687.1M | −$2.1M | ||||||
| Antero Res CorpCOM · shares +7.5% · price +4.5% | 5.1% | $527.8M | +$21.0M | ||||||
| Twenty First Centy Fox IncCL B · shares +8.6% · price +6.6% | 4.0% | $415.8M | +$23.7M | ||||||
| Cardinal Health IncCOM · shares 0% · price +2.3% | 3.1% | $319.7M | +$7.2M | ||||||
| Colony Northstar IncCL A COM · shares +3.7% · price −50.7% | 2.7% | $279.2M | −$277.4M | ||||||
| Pbf Energy IncCL A · shares −27% · price −4.4% | 2.6% | $268.6M | −$12.3M | ||||||
| Atara Biotherapeutics IncCOM · shares +17% · price +115.5% | 2.4% | $243.9M | +$112.0M | ||||||
| Mckesson CorpCOM · shares +19% · price −9.7% | 2.2% | $227.6M | −$20.5M | ||||||
| Theravance Biopharma IncCOM · shares 0% · price −13.1% | 2.2% | $225.7M | −$33.9M | ||||||
| Veritiv CorpCOM · shares +5.0% · price +35.6% | 1.4% | $149.9M | +$37.5M | ||||||
| Pg&E CorpCOM · shares New | 1.3% | $138.4M | — | ||||||
| Amerisourcebergen CorpCOM · shares −8.2% · price −6.1% | 1.1% | $113.6M | −$7.4M | ||||||
| Keryx Biopharmaceuticals IncCOM · shares 0% · price −12.0% | 1.0% | $105.5M | −$14.4M | ||||||
| Amc Entmt Hldgs IncCL A COM · shares 0% · price −7.0% | 0.68% | $70.3M | −$5.2M | ||||||
| Novagold Res IncCOM NEW · shares +25% · price +10.2% | 0.56% | $58.3M | +$4.3M | ||||||
| TeslaNOTE 2.375% 3/1 · shares New | 0.50% | $52.2M | — | ||||||
| Gty Technology Holdings IncUNIT 99/99/9999 · shares 0% · price +0.4% | 0.44% | $45.5M | +$161,000 | ||||||
| Paratek Pharmaceuticals IncCOM · shares 0% · price −27.4% | 0.30% | $31.1M | −$11.7M | ||||||
| Total 33 positions | 100% | $10.37B | −$325.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2017 to Q1 2018: 30 stocks held throughout, down $325.7M (−3.3%).
- Atara Biotherapeutics Inc+$112.0M+115%
- Twenty First Centy Fox Inc+$48.1M+6%
- Qorvo+$42.4M+6%
- Veritiv Corp+$37.5M+36%
- Time Warner Inc+$25.2M+3%
- Mckesson Corp−$20.5M−10%
- Theravance Biopharma Inc−$33.9M−13%
- Viasat Inc−$120.1M−12%
- Synchrony Finl−$148.8M−13%
- Colony Northstar Inc−$277.4M−51%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | $5.05B−7% | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | $5.42B+6% | SEC ↗ |
| Q1 2026 | May 14, 2026 | $5.12B−3% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $5.28B+10% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $4.79B+16% | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | $4.13B+18% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $3.50B+2% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $3.43B−2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $3.52B−3% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $3.63B−0% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $3.65B−20% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $4.59B−12% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $5.21B−7% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $5.61B−4% | SEC ↗ |
| Q1 2023 | May 12, 2023 | $5.85B−5% | SEC ↗ |
| Q4 2022 | Feb 13, 2023 | $6.13B+6% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $5.79B−14% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $6.77B−27% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $9.30B−8% | SEC ↗ |
| Q4 2021 | Feb 11, 2022 | $10.13B−7% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $10.88B−12% | SEC ↗ |
| Q2 2021 | Aug 13, 2021 | $12.33B−2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $12.56B+16% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $10.84B+17% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $9.25B+15% | SEC ↗ |
| Q2 2020 | Aug 13, 2020 | $8.01B+18% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $6.77B−25% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $9.06B+3% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $8.83B−20% | SEC ↗ |
| Q2 2019 | Aug 13, 2019 | $11.05B−7% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $11.90B+3% | SEC ↗ |
| Q4 2018 | Feb 13, 2019 | $11.52B−12% | SEC ↗ |
| Q3 2018 | Nov 15, 2018 (amended) | $13.06B+14% | SEC ↗ |
| Q2 2018 | Aug 13, 2018 | $11.44B+10% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $10.37B+3% | SEC ↗ |
| Q4 2017 | Feb 13, 2018 | $10.11B+26% | SEC ↗ |
| Q3 2017 | Nov 13, 2017 | $8.02B−8% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $8.75B+3% | SEC ↗ |
| Q1 2017 | May 25, 2017 (amended) | $8.49B+11% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $7.67B+9% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $7.04B−4% | SEC ↗ |
| Q2 2016 | Aug 12, 2016 | $7.37B+6% | SEC ↗ |
| Q1 2016 | May 13, 2016 | $6.92B | SEC ↗ |